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This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE), en-
dorsed by the European Society for Radiotherapy and Oncology (ESTRO), the European Society of Diges-
tive Endoscopy (ESDO), and the European Society for Clinical Nutrition and Metabolism (ESPEN). The
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was adopted
to define the strength of recommendations and the quality of evidence.
Main recommendations for malignant disease
1ESGE recommendsplacementof partiallyor fully
covered self-expandable metal stents (SEMSs) for
palliative treatment of malignant dysphagia over
laser therapy, photodynamic therapy, and esopha-
geal bypass (strong recommendation, high quality
evidence).
2 For patientswith longer life expectancy, ESGE re-
commends brachytherapy as a valid alternative or
in addition to stenting in esophageal cancer pa-
tients with malignant dysphagia. Brachytherapy
may provide a survival advantage and possibly a
better quality of life compared to SEMS placement
alone. (Strong recommendation, high quality evi-
dence.)
3 ESGE recommends esophageal SEMS placement
as the preferred treatment for sealing malignant
tracheoesophageal or bronchoesophageal fistula
(strong recommendation, low quality evidence).
4 ESGE does not recommend the use of concurrent
external radiotherapy and esophageal stent treat-
ment. SEMS placement is also not recommended
as a bridge to surgery or prior to preoperative che-
moradiotherapy. It is associated with a high inci-
dence of adverse events and alternative satisfac-
tory options such as placement of a feeding tube
are available. (Strong recommendation, low quali-
ty evidence.)
Main recommendations for benign disease
1 ESGE recommends against the use of self-ex-
pandable stents (SEMSs) as first-line therapy for
the management of benign esophageal strictures
because of the potential for adverse events, the
availability of alternative therapies, and costs
(strong recommendation, low quality evidence).
2ESGE suggests considerationof temporaryplace-
ment of SEMSs as therapy for refractory benign
esophageal strictures (weak recommendation,
moderate evidence).
Stents shouldusually be removedatamaximumof
3 months (strong recommendation, weak quality
evidence).
3 ESGE suggests that fully covered SEMSs be pre-
ferred over partially covered SEMSs for the treat-
ment of refractory benign esophageal strictures,
because of their lackof embedment and ease of re-
movability (weak recommendation, low quality
evidence).
4 For the removal of partially covered esophageal
SEMSs that are embedded, ESGE recommends the
stent-in-stent technique (strong recommenda-
tion, low quality evidence).
5 ESGE recommends that temporary stent place-
ment can be considered for treating esophageal
leaks, fistulas, andperforations. The optimal stent-
ingduration remains unclear and should be indivi-
dualized. (Strong recommendation, low quality
evidence.)
6 ESGE recommends placement of a SEMS for the
treatment of esophageal variceal bleeding refrac-
tory to medical, endoscopic, and/or radiological
therapy, or as initial therapy for patientswithmas-
sive esophageal variceal bleeding (strong recom-
mendation, moderate quality evidence).
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Abbreviations
!
BMI body mass index
CI confidence interval
CSEMS covered self-expandable metal stent
ESDO European Society of Digestive Oncology
ESGE European Society of Gastrointestinal Endoscopy
ESPEN European Society for Clinical Nutrition and Metabolism
ESTRO European Society for Radiotherapy and Oncology
FCSEMS fully covered self-expandable metal stent
GEJ gastroesophageal junction
GRADE Grading of Recommendations Assessment,
Development and Evaluation
HR hazard ratio
PCSEMS partially covered self-expandable metal stent
PEG percutaneous endoscopic gastrostomy
PDT photodynamic therapy
RBES refractory benign esophgeal stricture
RR risk ratio or relative risk
RCT randomized controlled trial
RTCT radiotherapy combined with chemotherapy
SEMS self-expandable metal stent
SEPS self-expandable plastic stent
TIPS transjugular intrahepatic portosystemic shunt
QoL quality of life
Introduction
!
Esophageal cancer is the eighth most common cancer worldwide
with an estimated 456000 new cases and 400000 deaths in 2012
[1]. More than 50% of patients with esophageal carcinoma have
metastatic disease at the time of diagnosis. Dysphagia is the
most common symptom of incurable obstructive esophageal
cancer and can be treated by esophageal stent placement. In re-
cent years different designs of esophageal stents have emerged
for improving dysphagia and quality of life in patients with ma-
lignant esophageal tumor, malignant fistula, or extrinsic com-
pression [2,3]. Esophageal stent placement in patients with in-
curable esophageal cancer is aimed at maintaining oral intake
and improving quality of life, but it carries a risk of adverse events
such as hemorrhage, pain, and fistula [4]. The current variety of
commercially available stents for malignant disease comprises
uncovered self-expandable metal stents (SEMSs); fully covered
self-expandable metal stents (FCSEMSs), in which the entire
length of the stent is covered; partially covered self-expandable
metal stents (PCSEMSs), in which the proximal and distal ends
of the stent are devoid of a covering; and fully covered self-ex-
pandable plastic stents (SEPSs). All currently available SEMSs are
made of nitinol, a nickel and titanium alloy. In Europe, the types
of stents that are predominately used in the treatment of malig-
nant dysphagia are PCSEMSs and FCSEMSs.
Esophageal stents are also commonly used for the treatment of
benign esophageal diseases, albeit most stents are not officially
approved for this indication. Common and investigative indica-
tions include treatment of refractory benign esophageal stricture
(RBES), sealing of perforations, leaks, and treatment of acute
esophageal variceal bleeding. FCSEMS and PCSEMS as well as
SEPS are used for this indication, but only the latter has formal
approval for RBES.All stents used for benign esophageal condi-
tions should be removed, except for the self-expandable biode-
gradable stents that have recently become available in Europe.
This clinical Guideline aims to describe the role of esophageal
stents in patients with malignant or benign esophageal disease
and makes recommendations on circumstances that warrant
their use.
Methods
!
The European Society of Gastrointestinal Endoscopy (ESGE)
commissioned this Guideline and appointed a Guideline leader
(M.J.B.) who invited the listed authors. The key questions were
prepared by the coordinating team (M.C.W.S., J.-M.D., C.H., M.J.
B.) and then approved by the other members (see Appendix e1,
available online). The coordinating team established task force
subgroups, each with a leader (P.D.S. for malignant disease and
T.H.B. for benign disease), and divided the key topics among
these task forces.
Each task force performed a systematic literature search to pre-
pare evidence-based and well-balanced statements on their as-
signedkeyquestions. All selectedarticleswere graded for the level
of evidence and strength of recommendation according to the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system [5]. The numbers of articles retrieved
and selectedbyeach task force are indicated in the evidence tables
(see●" Tablese1–e6 in Appendix e2, available online).
Each task force proposed statements for their assigned key ques-
tions, which were discussed during a meeting in Amsterdam
(April 2015). In August 2015, a draft prepared by the coordinating
team was sent to all group members. It was also sent for review
and endorsement to the European Society for Radiotherapy and
Oncology (ESTRO), the European Society of Digestive Oncology
(ESDO), and the European Society for Clinical Nutrition and Me-
tabolism (ESPEN). The manuscript was reviewed by two mem-
bers of the ESGE Governing Board and sent for further comments
to the National Societies and ESGE Individual Members. After
agreement on a final version, the manuscript was submitted to
Endoscopy for publication, All authors agreed on the final revised
manuscript.
This Guideline was issued in 2016 and will be considered for re-
view and update in 2021 or sooner if new and relevant evidence
becomes available. Any updates to the Guideline in the interim
will be noted on the ESGE website: http://www.esge.com/esge-
guidelines.html.
Recommendations and statements
!
ESOPHAGEAL STENTS IN MALIGNANT DISEASE
ESGE recommends placement of partially or fully covered self-expanding
metal stents (SEMSs) for palliation of malignant dysphagia over laser therapy,
photodynamic therapy, and esophageal bypass (strong recommendation,
high quality evidence).
ESGE recommends against the placement of nonexpandable and expandable
plastic stents for the palliation of malignant esophageal strictures (strong re-
commendation, high quality evidence).
Efficacy
Photodynamic therapy (PDT), laser therapy, and esophageal by-
pass have not been shown to be superior to SEMS placement for
the palliation of malignant dysphagia in several randomized con-
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trolled trials (RCTs) [6–11]. From 1993 up to 2005 several RCTs
have compared SEMS versus rigid plastic stents [12–18]. One of
the largest published RCTs including 217 patients [17] showed a
better improvement in dysphagia score at 1 and 6 weeks with
SEMS compared to rigid plastic stents and fewer late adverse
events. Systematic reviews and meta-analyses showed that
SEMS insertionwas superior to rigid plastic stents in terms of im-
provement and recurrence of dysphagia, as well as occurrence of
adverse events including perforation and migration [19,20].
Multiple types of self-expandable stents are available. They differ
in terms of design, luminal diameter, radial force, flexibility, and
degree of shortening after deployment. In Europe, partially or
fully covered SEMS are used for the treatment of malignant dys-
phagia because recurrent dysphagia due to tumor ingrowth has
been a major drawback of uncovered SEMSs [21]. In most cases
a 100% technical success rate of stent placement has been report-
ed with an improvement in dysphagia score of at least 2 points
(from 3 [liquids only] to 1 [almost all solids]) within 1–2 days
[20]. Most new stent designs have been evaluated in single-arm
prospective or retrospective series. SEPS are similar to SEMS
with regard to relief of dysphagia in the short term, but adverse
events occurred more often with SEPS, especially migration,
making SEMS preferable over SEPS for malignant dysphagia [22].
Safety
The most prevalent adverse events following stent placement are
shown in●" Tablee7 (Appendix e3, available online) and details
are also presented in Appendix e3. Analysis of pooled data from
RCTs and prospective and retrospective studies showed that ma-
jor adverse events occur in 18%, 21%, and 10% of patients with
PCSEMS, FCSEMS, and SEPS, respectively, while recurrent dys-
phagia develops in 41%, 29%, and 37% of these patients, respec-
tively [22–39]. Stent insertion-related mortality is 0%–2%
[23, 40].
For patients with longer life expectancy, ESGE recommends brachytherapy as
a valid alternative or in addition to stenting in esophageal cancer patients with
malignant dysphagia. Brachytherapy may provide a survival advantage and
possibly a better quality of life compared to SEMS placement alone. (Strong
recommendation, high quality evidence.)
Two RCTs have compared SEMS versus brachytherapy. One RCT
compared a PCSEMS (Ultraflex) with single-dose intraluminal
brachytherapy in 202 patients with incurable esophageal cancer
[4]. Compared to SEMS placement, brachytherapy improved dys-
phagia less rapidly, but after 1 month from treatment, dysphagia
score improvement no longer differed significantly between
stent placement and brachytherapy. With respect to survival, pa-
tients treated by brachytherapy had more days with almost no
dysphagia during follow-up than those treated by stent place-
ment. In addition, major complications (i.e., perforation, hemor-
rhage) occurred more frequently after stent placement than after
brachytherapy. There was no difference in recurrent dysphagia
and median survival. Quality-of-life (QoL) scores significantly fa-
vored brachytherapy, whereas total costs were similar across the
two groups. In the other RCT (n=65), insertion of SEMS offered a
more immediate relief of dysphagia compared to brachytherapy,
but quality of life was better with brachytherapy for patients
with longer survival [41]. The main limitations of brachytherapy
include limited availability, technical difficulty, and need for
dedicated logistics and expertise. Therefore this treatment can
only be considered in dedicated centers.
Esophageal stent placement for malignant
tracheoesophageal or bronchoesophageal fistula
Esophageal SEMS placement is recommended as the preferred treatment for
sealing malignant tracheoesophageal or bronchoesophageal fistula (strong
recommendation, low quality evidence).
Application of double stenting (esophagus and airways) can be considered
when fistula occlusion is not achieved by esophageal or airway prosthesis
alone (strong recommendation, low quality evidence).
Malignant tracheoesophageal or bronchoesophageal fistula de-
velops in 5% to 15% of patients with esophageal cancer and in
less than 1% of patients with lung carcinoma [42,43]. Because of
advances in palliative treatment, the incidence has increased
over the last 30 years to above 10% among all nonresected esoph-
ageal cancers [44].
Tracheoesophageal or bronchoesophageal fistulas are usually late
developments of advanced cancer of the esophagus, lung, or
mediastinum, caused by tumoral invasion or as an adverse event
of cancer therapies, in particular chemoradiotherapy [45–47].
Importantly, the condition of such patients has often already sig-
nificantly deteriorated when they develop a fistula and the re-
maining life expectancy is short (weeks to months). Rapid relief
of disabling symptoms due to the fistula, preferably by minimally
invasive treatment, is thus of pivotal importance in order to im-
prove quality of life.
Esophageal stenting is the most widely used approach [48]. Mul-
tiple studies using SEMSs for sealing off esophageal – airway fis-
tulas have reported improvement in symptoms and sealing of the
fistula in 75%–100% of patients [2,42,43,49–55]. Application of
double stenting (esophagus and airways) can be considered
when fistula occlusion is not achieved by esophageal or airway
prosthesis alone [51,56–58]. In the largest prospective series,
Shin et al. successfully placed SEMSs in 61 patients with malig-
nant esophageal–airway fistulas, sealing off the fistula in 49 pa-
tients (80%), while 10 patients (16%) required concomitant air-
way stents [42]. Re-opening of the fistula occurred in 17 patients
(35%); of these, 8 were successfully re-treated with SEMSs, in 2
patients the fistula was closed spontaneously, and 7 patients did
not undergo further treatment [42].
Procedure-related complications are reported in 0%–27% of pa-
tients with a mortality rate of 0%–12% [42,43,49,50,52,54].
In another study that compared quality of life following place-
ment of a SEMS versus gastrostomy or jejunostomy or best sup-
portive care, quality of life improvedmore with SEMS placement,
particularly for symptoms of dyspnea, dysphagia, other eating
problems, dry mouth, cough, and hypersalivation [59]. In three
large retrospective studies, esophageal stent placement was
associated with a significant improvement in survival compared
with no sealing of the fistula, a feeding gastrostomy or jejunost-
omy, or best supportive care [42,43,50].
Stent placement for malignant dysphagia as a bridge
to surgery
ESGE does not recommend SEMS placement as a bridge to surgery or prior to
preoperative chemoradiotherapy. It is associated with a high incidence of ad-
verse events, and other satisfactory options such as placement of a feeding
tube are preferable. (Strong recommendation, low quality evidence.)
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It is now accepted that neoadjuvant chemotherapy or chemora-
diotherapy should be administered to all patients with a resect-
able esophageal cancer, except for cancers staged 0– IIA [60–62].
In a systematic review andmeta-analysis of 9 studies (n=180 pa-
tients) on esophageal stenting preceding or concomitant with
neoadjuvant chemotherapy for esophageal cancer, the procedur-
al success rate was 95% (95% confidence interval [95%CI] 90%–
98%) [63]. There was a significant decrease in dysphagia score
and a nonsignificant increase in patient weight (0.6kg) and se-
rum albumin. However, major adverse events were extremely
frequent, including stent migration (incidence 32%, 95%CI 26%–
40%) and chest discomfort (incidence 51.4%, 95%CI 21%–81%).
SEPS were used in 5 of the 9 studies (41% of patients). The nega-
tive impact on oncologic outcome of SEMS placement as bridge to
surgery was also confirmed in a large European cohort of 2944
patients [64]. This study showed an in-hospital postoperative
mortality and morbidity rate for the SEMS versus control groups
of 13.2% versus 8.6% and 63.2% versus 59.2%, respectively. In ad-
dition, significant differences in R0 resection (71.0% vs. 85.5%),
median time to recurrence (6.5 vs. 9.0 months), and 3-year over-
all survival (25% vs. 44%) were found, to the disadvantage of the
SEMS group.The results remained significant after excluding
SEMS-related esophageal perforations and after adjusting for
confounding factors. Similar unfavorable results have been re-
ported with biodegradable stents as a bridge to surgery [65].
Profound weight loss and malnutrition as a consequence of se-
vere dysphagia and cancer cachexia are cardinal symptoms in
esophageal cancer [66,67]. To detect nutritional disturbances at
an early stage, the European Society for Clinical Nutrition and
Metabolism (ESPEN) recommends regular evaluation of nutri-
tional intake, weight change, and body mass index (BMI), at the
time of cancer diagnosis and repeated according to the stability
of the clinical situation [68]. In patients with digestive cancer,
body composition may be quite easily assessed from computed
tomography scans [69]. ESPEN recommends nutritional support
prior to major surgery in patients with severe nutritional risk (e.
g., those with weight loss>10–15% within 6 months) as a grade
A recommendation [70]. If oral feed intake is inadequate despite
counseling and oral nutritional supplements, supplemental ent-
eral nutrition or, if the latter is not sufficient or possible, parent-
eral nutrition is recommended [68,71]. In patients with severe
dysphagia, this can be achieved through nasogastric tube place-
ment, percutaneous feeding tube placement, or parenteral nutri-
tion. Percutaneous endoscopic gastrostomy (PEG) or endoscopic
jejunostomy is recommended by ESPEN in place of nasogastric
tube placement if enteral feeding is scheduled to last more than
2–3 weeks [72,73]. Furthermore, a Cochrane review of RCTs
showed that intervention failure (e.g., feeding interruption,
blocking or leakage of the tube, no adherence to treatment) was
more frequent with nasogastric tube placement compared with
PEG feeding (risk ratio [RR] 0.24, 95%CI 0.08–0.76) [74]. How-
ever, in esophageal cancer patients who are scheduled to under-
go a gastric tube reconstruction a PEG placement may be contra-
indicated, in which case a feeding tube is the preferred treat-
ment. The proportion of patients who refuse placement of a feed-
ing tube in the setting of head and neck cancer patients treated
with (chemo)radiation has been found to be very low (4% in an
RCT) [75].
Esophageal stents and concomitant palliative treatment
with radiotherapy
ESGE does not recommend the concurrent use of radiotherapy if an esopha-
geal stent is present (strong recommendation, low quality evidence).
ESGE suggests that SEMS placement with concurrent single-dose brachyther-
apy is safe and effective for relief of dysphagia (weak recommendation, low
quality evidence).
In contrast to the rapid improvement in dysphagia by stent place-
ment, palliative radiotherapy improves dysphagia after 4 to 6
weeks [76]. Temporary and permanent placement of retrievable
metallic stents with concurrent radiotherapy has been suggested
as an effective method for increasing survival, immediately im-
proving dysphagia and dietary intake in the period before the ef-
fects of radiotherapy become apparent [77–80]. However, a
higher risk of life-threatening adverse events has been reported,
suggesting that palliative stenting should be delayed until radio-
therapy has failed [81–83].
Potential scattering from the metal material in SEMSs may com-
plicate radiation dosimetry. In a simulated clinical protocolmeas-
uring the effects of esophageal stents of various materials and de-
signs on radiation effects on tissue adjacent to the stent in the ra-
diation field, a dose enhancement was seenwith SEPSs and stain-
less steel stents, and not with nitinol stents [84]. In another study,
dose perturbation by SEMSs was related to the density of the
mesh, with a higher density having greater effect, while SEPS
and biodegradable stents had minimal-to-no dose effects outside
of the radiopaque markers [85].
In contrast to external radiotherapy, the combination of SEMS
and single-dose brachytherapy has been reported to be feasible
and safe as a palliative treatment in patients with advanced
esophageal cancer [77,86]. In an RCT that included 53 patients,
Guo et al. compared conventional SEMS treatment with SEMS
loaded with iodine-125 seeds for brachytherapy; these authors
reported a significantly longer dysphagia-free period and longer
survival in the irradiation stent group [25,87].
Data on the use of biodegradable stents in patients receiving bra-
chytherapy are limited, but a high rate of major stent-related
complications has been described and a normal diet could not
be tolerated because of retrosternal pain and vomiting in more
than one third of patients [78].
Esophageal stent placement after palliative
chemotherapy and radiotherapy
Data are contradictory with respect to the risk of major ad-
verse events in patients receiving a stent for recurrent malig-
nancy following radiotherapy alone or combined with chemo-
therapy (RTCT). Some studies show an increased risk while
other studies, including a meta-analysis, do not report any
relationship between SEMS placement after RTCT and the inci-
dence of life-threatening adverse events or survival; only mi-
nor adverse events such as chest pain are associated, suggest-
ing stenting is safe in these patients [18,22,32,88–94]. In de-
tail, the reported rate of life-threatening adverse events
ranged from 16% to 77% in patients treated with stents after
RTCT compared to 0% to 45% in patients without previous
treatment [18,22,32,88–91]. Reported stent-related mortality
ranged from 0% to 54% in patients with prior RTCT compared
to 0% to 6% in patients without prior RTCT.
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It has been suggested that the increased risk, if any, of developing
life-threatening adverse events, in patients with prior RTCT may
be related to the radiation-induced damage on the esophageal
wall, potentiated by chemotherapy. However, it is difficult to dis-
cern whether such stent-related adverse events are due to stents
and radiation effects, the advanced nature of the disease process,
or both. Radiotherapy can cause esophagitis, ulcerations, submu-
cosal fibrosis, and vasculitis, with ischemic damage of the esoph-
ageal wall causing esophageal perforations and esophageal–re-
spiratory fistulas via local hypoxemia. Although SEMS placement
is effective for short-term palliation of malignant dysphagia, stent
pressure on a damaged esophageal wall increases the risk of ne-
crosis [89,95–99]. The effect of radiation on the esophageal wall
is dose-dependent, with serious damage especially when doses
greater than 6Gy have been administered [97,99]. The risks of
sudden fatal hemorrhage and formation of a respiratory fistula
are relatively high in patients with invasive (T4) cancer [47,96].
ESOPHAGEAL STENTS IN BENIGN DISEASE
Refractory benign strictures
ESGE recommends against the use of SEMSs as first-line therapy for the man-
agement of benign esophageal strictures because of the potential for adverse
events, the availability of alternative therapies, and costs (strong recommen-
dation, low quality evidence).
Most studies have used expandable stents for treatment of re-
fractory or recurrent esophageal strictures as defined by Koch-
man: generally when more than 3 to 5 dilations (either mechan-
ical or pneumatic) have been performed without clinical and
endoscopic response or when it was impossible to achieve a 14-
mm lumen over 3 dilation sessions [100]. No studies have com-
pared the clinical efficacy of different initial strategies (i. e., dila-
tion vs. stent placement). Therefore, algorithms are mainly based
on the experience of tertiary referral centers [101]. Most experts
agree that stent placement should be considered when other
treatment options (dilation with or without intralesional triam-
cinolone acetate injections and/or incisional therapy) have failed,
though a clear definition of clinical failure has not been uniformly
adopted.
ESGE suggests consideration of temporary placement of self-expandable
stents for refractory benign esophageal strictures (weak recommendation
moderate quality evidence).
ESGE does not recommend a specific type of expandable stent (covered met-
al, plastic, biodegradable) because none has been shown to be superior to any
other for this indication (strong recommendation, moderate quality evi-
dence).
A recent systematic review and meta-analysis (10 prospective
and 8 retrospective studies; 444 patients) evaluated the clinical
outcome of stent placement for refractory benign esophageal
stricture (RBES) [102]. FCSEMS were used in 9 studies (227 pa-
tients), 8 trials used SEPS (140 patients) and 4 studies used bio-
degradable stents (77 patients). Overall, the pooled clinical suc-
cess rate was 40.5% (95%CI 31.5%–49.5%). Patients treated with
SEPS and SEMS did not have significantly different success rates
compared with patients treated with biodegradable stents. The
overall migration rate was 28.6% (95%CI 21.9%–37.1%). Stent re-
moval was successful in 99% of cases. Finally, the overall adverse
event rate was 20.6% (95%CI, 15.3%–28.1%) with no significant
difference between the three types of stents. Only one patient
died; this was due to massive bleeding.
Factors predicting successful stent treatment
A systematic review demonstrated that the clinical success of
stenting in RBES was significantly lower in patients with cervical
strictures and for strictures longer than 2cm [100]. The latter
finding was confirmed by a prospective study showing stricture
length as the only factor associated with success, with longer
strictures being at higher risk of recurrence (hazard ratio [HR]
1.37, 95%CI 1.08–1.75) [103]. The previously mentioned review
and meta-analysis by Fuccio et al. [102] showed that the etiology
of the stricture might influence outcome, with esophageal stric-
tures that had developed after surgical resection or radiation
therapy being potentially more responsive to stent treatment.
However, no firm conclusion can be drawn because many etiolo-
gies of stricture were under-represented and, in many studies,
the results were not stratified according to the stricture etiology.
ESGE does not recommend permanent stent placement for refractory benign
esophageal stricture; stents should usually be removed at a maximum of 3
months (strong recommendation, weak quality evidence).
No studies have compared different strategies in terms of stent-
ing duration. It is generally accepted that FCSEMSs or SEPSs
should remain in place for at least 6–8 weeks and no more than
12 weeks, tomaximize success and tominimize the risk of hyper-
plastic tissue reaction and stent embedment. Indeed, a largemul-
ticenter study that specifically addressed the safety of endoscopic
removal of self-expandable stents inserted to treat RBES found no
association between indwelling time and the risk of major ad-
verse events [104].
ESGE suggests that FCSEMSs be preferred over PCSEMSs for the treatment of
refractory benign esophageal stricture, because of their lack of embedment
and ease of removability (weak recommendation, low quality evidence).
The use of partially covered or uncovered SEMS in benign stric-
tures should be avoided because the hyperplastic tissue reaction
of the esophageal mucosa to the bare metal mesh often results in
recurrent dysphagia. Furthermore, complete embedding of the
uncovered metal wires in the esophageal wall may preclude safe
stent removal [105,106].
ESGE recommends the stent-in-stent technique to remove PCSEMSs that are
embedded in the esophageal wall (strong recommendation, low quality evi-
dence).
In the case of embedded PCSEMSs, temporary placement of a sec-
ond, fully covered, stent in the first stent (“stent-in-stent” tech-
nique) has been shown to facilitate safe removal of the embedded
stent, by induction of pressure necrosis of the overgrowing and
ingrowing mucosa [103,107–110]. Stents used for the stent-in-
stent technique should have a fully covered design and a diame-
ter at least equal to that of the partially covered embedded stent
in order to provide sufficient pressure at the site of embedment.
In addition, the fully covered stent needs to overlap completely
tissue ingrowth inside the lumen of the partially covered stent.
The second stent is left in place for 10–14 days, before it is re-
trieved and removal of the embedded PCSEMS is attempted. The
success rate of the stent-in-stent technique is above 90%; in the
case of failure, a second FCSEMS should be placed and left in
place for 10–14 days before a second attempt to remove the stent
is performed [103].
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Esophageal stent placement in combination with other dilation
approaches
ESGE suggests that a combined approach of stent placement with additional
techniques (e.g., corticosteroid injection, chemotherapeutic topical applica-
tion) should not be used in an attempt to improve the long-term benefit of
temporary stenting (weak recommendation, very low quality evidence).
Endoscopic incisional therapy has been proposed as either an al-
ternative or additional treatment to endoscopic dilation. Initially
proposed for the treatment of recurrent Schatzki rings, it has also
been used for the treatment of anastomotic strictures. To our
knowledge there have been no studies that have reported using
a combined or sequential approach with incisional therapy fol-
lowed by stent placement.
In order to prevent stricture recurrence, corticosteroid injection
into the stricture followed by dilation was proposed more than
10 years ago [111]. Small retrospective studies reporting corti-
costeroid injection before stent placement do not allow conclu-
sions to be drawn on the additional clinical value for prolonging
efficacy following temporary stent placement [112].
Topical application of mitomycin-C has been proposed for refrac-
tory corrosive esophageal strictures. Mitomycin-C is a chemo-
therapeutic agent that inhibits the proliferation of fibroblasts
and collagen synthesis and has been proposed to prevent stric-
ture relapse. There are few available studies, mainly case reports
and small series, to support its use, and no studies of this treat-
ment combined with stent placement [113,114].
Treatment options after stent failure for refractory
benign esophageal stricture
If refractory benign esophageal stricture has not satisfactorily improved after
2 separate treatments with temporary stenting, ESGE suggests alternative
treatment strategies such as self-dilation or surgical treatment (weak recom-
mendation, low quality evidence).
In poor surgical candidates, ESGE recommends self-dilation with rigid dilators
(strong recommendation, low quality evidence).
Stent placement for treatment of RBES may be repeated although
the majority of studies have demonstrated that additional stent
placement does not produce significant incremental benefit
[106,115]. If sustained stricture resolution is not obtained after
temporary stenting on two occasions, the suggested treatment
options are self-dilation and surgery. Surgery is advised when
possible according to anatomical extent as well as patient condi-
tion and willingness to undergo such a complex surgical proce-
dure. The best candidates for self-dilation are those who are self-
motivated, compliant, and poor surgical candidates [116,117].
Based on two retrospective studies, esophageal self-dilation was
successful in treating 90% of patients, with significant improve-
ment in global dysphagia scores and overall quality of life [116,
117].
Benign esophageal leaks, fistulas, and perforations
ESGE recommends that temporary stent placement can be considered for
treatment of leaks, fistulas, and perforations. No specific type of stent can be
recommended and the duration of stenting should be individualized. (Strong
recommendation, low quality of evidence).
SEMSs have been used for management of perforations and leaks
[118,119]. Closure of an iatrogenic perforation can also be per-
formed by other endoscopic methods [120].●" Tablee5 (Appen-
dix e2, available online) shows the results of the published stud-
ies on the efficacy and safety of SEMS placement for benign rup-
ture and leakage. In two systematic reviews, the clinical success
after placement of temporary stents (FCSEMSs, PCSEMSs, and
SEPSs) for benign rupture and anastomotic leaks of the esopha-
gus was similar with different stent types (FSEMS 85%, PSEMS
86%, SEPS 84% [121,122]. The mean duration of stenting was 7
weeks. Stent migration occurred in 25%, and it occurred more of-
ten with SEPS (26%) and FCSEMS (26%).
Data on the use of biodegradable stents are limited. In a small
study, 4 of 5 patients with an esophageal leak or anastomotic per-
foration achieved long-term leak sealing after placement of a cov-
ered biodegradable stent [123].
The optimal duration of stenting remains unknown. In most
studies stent removal was performed 6–8 weeks (range 4–10
weeks) after insertion. Stent-associated esophagorespiratory fis-
tula is a serious adverse event that may occur as a consequence of
SEMS placement for benign disease. In one retrospective study of
397 patients, 20 patients developed esophagorespiratory fistulas
after amedian of 5months following stent placement [124]. Most
fistulas occurred at the proximal edge of the stent and in the set-
ting of prior external radiation therapy; thus the cause may have
been ischemic pressure necrosis.
Acute variceal bleeding
ESGE recommends considering placement of a SEMS for the treatment of
esophageal variceal bleeding refractory to medical, endoscopic, and/or ra-
diological therapy, or as initial therapy for patients with massive bleeding
(strong recommendation, moderate quality evidence).
●" Tablee6 (Appendix e2, available online) shows the results of the
published studies to date on the applicability, efficacy and safety
of covered SEMS for acute esophageal variceal bleeding [125–
131] Most published studies are observational studies [125–
131]. Results from these studies are in agreement with a recently
published systematic review and meta-analysis showing that
treatment with SEMSs is successful in controlling severe or refrac-
tory acute variceal bleeding, without the occurrence of severe ad-
verse events andwith a 1-month survival ofmore than 60%; these
findings confirmed that this therapy can be used as a bridge to
transjugular intrahepatic portosystemic shunt (TIPS) or liver
transplantation in a significant proportion of patients [132].
An RCT compared patient outcome after SEMS placement (SX-
Ella Danis stent; n=13) versus balloon tamponade (Sengstaken-
Blakemore tube; n=15) in patients with esophageal variceal
bleeding refractory to medical and endoscopic treatment [133].
Successful therapy was significantly more frequent in the stent
than in the balloon tamponade group (66% vs. 20%) with a signif-
icantly higher rate for control of bleeding (85% vs. 47%), lower
transfusion requirements (3±3.4 vs. 6±4.8 packed red blood cell
units), and a lower incidence of serious adverse events (15% vs.
47%), mainly due to differences in aspiration pneumonia (0 vs.
5) and esophageal tear (1 patient in the balloon tamponade
group). No significant difference in 6-week survival was observed
(54% vs. 40%).
Despite the efficacy of stent placement in controlling acute vari-
ceal bleeding, a mortality rate of 25% has been described in these
patients, reflecting the seriousness of the underlying condition of
the patient in the case of refractory acute variceal bleeding [129].
In published studies SEMSs have remained in place for up to 2
weeks [125,131,134,135]. When a dedicated SEMS is used re-
trieval is done using a specifically designed system (PEX-Ella or
extractor for SX-Ella Stent Danis).
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This Guideline, produced by ESGE and endorsed by the European
Society for Radiotherapy and Oncology (ESTRO), the European
Society of Digestive Oncology (ESDO), and the European Society
for Clinical Nutrition and Metabolism (ESPEN), represents a con-
sensus of best practice based on the available evidence at the
time of preparation. The Guideline may not apply in all situations
and should be interpreted in the light of specific clinical situa-
tions and resource availability. Further controlled clinical studies
may be needed to clarify aspects of the statements, and revision
may be necessary as new data appear. Clinical consideration may
justify a course of action at variance to the recommendations.
The Guidelines is intended to be an educational device to provide
information that may assist endoscopists in providing care to pa-
tients. It is not a set of rules and should not be construed as estab-
lishing a legal standard of care or as encouraging, advocating, re-
quiring, or discouraging any particular treatment.
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